References
  1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506.
  2. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6): 683-690.
  3. Ghannam M, Alshaer Q, Al-Chalabi M, et al. Neurological involvement of coronavirus disease 2019: a systematic review. J Neurol. 2020; 267(11): 3135-3153.
  4. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: A case-control study. Lancet. 2016; 387(10027): 1531-1539.
  5. Kim JE, Heo JH, Kim HO, et al. Neurological complications during treatment of middle east respiratory syndrome. J Clin Neurol. 2017; 13(3): 227-233.
  6. Keddie S, Pakpoor J, Mousele C, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2021; 144(2): 682-693.
  7. McGrogan A, Madle GC, Seaman HE, et al. The epidemiology of Guillain-Barre syndrome worldwide. A systemic literature review. Neuroepidemiology. 2009; 32(2): 153-163.
  8. Filosto M, Piccinelli SC, Gazzina S, et al. Guillain-Barre syndrome and COVID-19: A 1-year observational multicenter study. Eur J Neurol. 2022; 10.1111/ene.15497.
  9. Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain-Barre syndome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021; 268(4):1133-1170.
  10. Oguz-Akarsu E, Ozpar R, Mirzayev H, et al. Guillain-Barré Syndrome in a Patient With Minimal Symptoms of COVID-19 Infection. Muscle Nerve. 2020; 62(3): E54-E57.
  11. Aladawi M, Elfil M, Abu-Esheh B, et al. Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review. Can J Neurol Sci. 2022; 49(1): 38-48.
  12. Hartung HP, Toyka KV. T-cell and Macrophage Activation in Experimental Autoimmune Neuritis and Gullain-Barre Syndrome. Ann Neurol. 1990; 27: S57-63.
  13. Caress JB, Castoro RJ, Simmons Z, et al. COVID-19-associated Guillain-Barré syndrome: The early pandemic experience. Muscle Nerve. 2020; 62(4):485-491.
  14. Faqihi F, Alharthy A, Memish ZA, et al. Peripheral neuropathy in severe COVID-19 resolved with therapeutic plasma exchange. Clin Case Rep. 2020; 8(12): 3234-3239.
  15. Shang P, Feng J, Wu W, et al. Intensive Care and Treatment of Severe Guillain-Barre Syndrome. Front Pharmacol. 2021; 12: 608130.
  16. Van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med. 1992; 326(17): 1123-9.
  17. Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021; 27(12): 2144-2153.